Baltimore, Maryland - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB – NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis.
"A series of recent landmark events in the marijuana and medical marijuana space, along with a revaluation of biotechs, are set to serve as triggers prompting the accumulation and rise of Nuvilex’s stock back to the levels enjoyed roughly 9 months ago."
Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-BoxTM, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-BoxTM technology may play a role in these efforts.
According to Goldman, the aforementioned triggers include a surge of interest in, and validation of, medical marijuana and the publicly traded firms that operate in the space. Catalysts cited in the research update include a tacit marijuana endorsement by President Obama, which could give a huge shot in the arm to the sector. Plus, given that Colorado’s tax revenue-generating pot shops cannot keep product on the shelves, cash-strapped states and municipalities may view a softening stance on this topic as a tangible opportunity to generate real revenue.
In addition, the swift and broad shift in support toward medical marijuana will likely be enhanced during the 2- week Super Bowl marketing period. Since the two participants hail from the states that have legalized marijuana, it is likely that proponents will flood the media with stories on the topic, placing it near the top of the talking points food chain.
Finally, Goldman notes that major moves have occurred of late in other anti-cancer stocks while biotech investors seek to find the next biotech slated to move in concert with the launch of upcoming events. With a series of milestone events ahead for the Company, investors could enjoy similar moves as these milestones are achieved, as evidenced by the achievements of its peer group and the subsequent rises in their stock prices.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A sponsored Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB – NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: www.nuvilex.com.
Goldman Small Cap Research
Rob Goldman, Analyst
Leave a comment...